197 related articles for article (PubMed ID: 34247263)
1. Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study.
Shiraki M; Kuroda T; Takeuchi Y; Sugimoto T; Tanaka S; Suzuki H; Hiraishi K; Nakamura T
Calcif Tissue Int; 2021 Dec; 109(6):666-674. PubMed ID: 34247263
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of non-steroidal anti-inflammatory drugs on zoledronic acid-induced acute-phase reactions: randomized, open-label, Japanese OZ study.
Okimoto N; Sakai A; Yoshioka T; Kobayashi T; Asano K; Akahoshi S; Ishikura T; Fukuhara S; Fuse Y; Mizuno T; Katae Y; Matsumoto H; Ogawa T; Nishida S; Ikeda S; Menuki K; Saito J; Okazaki Y; Mizuno N; Fujiwara S
J Bone Miner Metab; 2020 Mar; 38(2):230-239. PubMed ID: 31586241
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
[TBL] [Abstract][Full Text] [Related]
4. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
[TBL] [Abstract][Full Text] [Related]
5. The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial.
Black DM; Reid IR; Napoli N; Ewing SK; Shiraki M; Nakamura T; Takeuchi Y; Schafer AL; Kim TY; Cauley JA
J Bone Miner Res; 2022 Jan; 37(1):21-28. PubMed ID: 34585443
[TBL] [Abstract][Full Text] [Related]
6. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM; Reid IR; Cauley JA; Cosman F; Leung PC; Lakatos P; Lippuner K; Cummings SR; Hue TF; Mukhopadhyay A; Tan M; Aftring RP; Eastell R
J Bone Miner Res; 2015 May; 30(5):934-44. PubMed ID: 25545380
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
8. The role of zoledronic acid in the management of osteoporosis.
Maricic M
Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
[TBL] [Abstract][Full Text] [Related]
9. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
10. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
Crotti C; Watts NB; De Santis M; Ceribelli A; Fabbriciani G; Cavaciocchi F; Marasini B; Selmi C; Massarotti M
Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
[TBL] [Abstract][Full Text] [Related]
12. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
13. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
[TBL] [Abstract][Full Text] [Related]
14. Addition of dexamethasone to manage acute phase responses following initial zoledronic acid infusion.
Chen FP; Fu TS; Lin YC; Lin YJ
Osteoporos Int; 2021 Apr; 32(4):663-670. PubMed ID: 33113007
[TBL] [Abstract][Full Text] [Related]
15. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
16. Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery.
Kashii M; Kamatani T; Abe S; Yoshida A; Yamamoto K; Koizumi K; Mizuno N; Kuriyama K; Yoshikawa H
Bone; 2022 Feb; 155():116298. PubMed ID: 34906743
[TBL] [Abstract][Full Text] [Related]
17. Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study.
Eastell R; Boonen S; Cosman F; Reid IR; Palermo L; Cummings SR; Black DM
J Bone Miner Res; 2015 Mar; 30(3):570-4. PubMed ID: 25214069
[TBL] [Abstract][Full Text] [Related]
18. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
Silverman SL; Kriegman A; Goncalves J; Kianifard F; Carlson T; Leary E
Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816
[TBL] [Abstract][Full Text] [Related]
19. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).
Black DM; Reid IR; Boonen S; Bucci-Rechtweg C; Cauley JA; Cosman F; Cummings SR; Hue TF; Lippuner K; Lakatos P; Leung PC; Man Z; Martinez RL; Tan M; Ruzycky ME; Su G; Eastell R
J Bone Miner Res; 2012 Feb; 27(2):243-54. PubMed ID: 22161728
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid in osteoporosis secondary to mastocytosis.
Rossini M; Zanotti R; Viapiana O; Tripi G; Idolazzi L; Biondan M; Orsolini G; Bonadonna P; Adami S; Gatti D
Am J Med; 2014 Nov; 127(11):1127.e1-1127.e4. PubMed ID: 24954632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
